We are pleased to announce that we have obtained CIR approval (Research Tax Credit) for three years, until 2026.
The Research Tax Credit is a scheme set up by the government to encourage companies to innovate and enhance their competitiveness.
By choosing Dev4All for their research activities, French companies will have the opportunity to boost their R&D without increasing their budgets thanks to the 30% tax credit.
Dev4All Health Science is the new R&D accelerator of 4P-Pharma.
